Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data
Nektar Therapeutics maintains a Hold rating as its valuation is closely linked to the prospects of REZPEG in treating atopic dermatitis. Recent Phase 2 data for REZPEG indicates modest efficacy, which may hinder its competitiveness against established treatments. Additionally, the outlook for alopecia areata appears weak due to missed Phase 2 endpoints and a limited target population.
- ▪Nektar Therapeutics has a Hold rating based on REZPEG's prospects.
- ▪Phase 2 data for REZPEG shows modest efficacy in atopic dermatitis.
- ▪The outlook for alopecia areata is weak due to missed Phase 2 endpoints.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4908930-why-im-still-neutral-on-nektar-therapeutics-after-alopecia-areata-extension-data"},"author":{"@type":"Person","name":"Stephen Ayers","url":"https://seekingalpha.com/author/stephen-ayers"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
